603676 Xizang Weixinkang Pharmaceutical
- 9.87
- -0.26-2.57%
Xizang Weixinkang Pharmaceutical News
Express News | Tibet Weixinkang Pharmaceutical: Subsidiary withdraws the registration application for compound amino acids (16) dipeptide (1) injection.
tibet weixinkang pharmaceutical (603676.SH): Compound Electrolyte Injection (II) Passes Generic Drug Consistency Evaluation
Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (简...
tibet weixinkang pharmaceutical (603676.SH) equity distribution in the first three quarters of 2024: 0.162 yuan per share, with equity registration on November 11th.
tibet weixinkang pharmaceutical (603676.SH) issued a notice on equity distribution for the first three quarters of 2024, and the profit distribution for this time is based on the plan...
Express News | tibet weixinkang pharmaceutical: Subsidiary pharmaceutical products have passed the evaluation of generic drug quality and efficacy consistency.
Tibet Weixinkang Pharmaceutical (603676) company brief report: The impact of centralized procurement is gradually being digested, and the performance is ushering in a turning point.
Event: The company released its Q3 report for 2024, achieving revenue of 0.994 billion yuan (-6.30%) in the first three quarters, with a net income attributable to shareholders of the listed company of 0.243 billion yuan (+15.71%), attributable to
tibet weixinkang pharmaceutical (603676.SH): Not yet repurchased
On November 4, tibet weixinkang pharmaceutical (603676.SH) announced that, as of October 31, 2024, the company has repurchased 0 shares.
Wei Xinkang: Report for the Third Quarter of 2024 of Tibet Weixinkang Pharmaceutical Co., Ltd.
Report for the third quarter of 2024 of Tibet Weixinkang Pharmaceutical Co., Ltd.
tibet weixinkang pharmaceutical (603676.SH): The net income for the first three quarters was 0.243 billion yuan, a year-on-year increase of 15.71%.
GeLongHui on October 28thཨTibet Weixinkang Pharmaceutical (603676.SH) released its third quarter report, with revenue of 0.994 billion yuan in the first three quarters, a 6.30% year-on-year decrease, a net income of 0.243 billion yuan, a 15.71% year-on-year increase, a non-GAAP net profit of 0.197 billion yuan, a 15.84% year-on-year increase, and basic earnings per share of 0.56 yuan.
Tibet Weixinkang Pharmaceutical (603676.SH) released its performance for the first three quarters, with a net income of 0.243 billion yuan, a year-on-year increase of 15.71%.
tibet weixinkang pharmaceutical (603676.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue of 9...
Tibet Weixinkang Pharmaceutical (603676.SH) subsidiary compound electrolyte injection (V) passed the generic drug consistency evaluation
Tibet Weixinkang Pharmaceutical (603676.SH) announced that recently, its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd...
Tibet Weixinkang Pharmaceutical (603676.SH): Obtained exclusive license for a non-opioid intravenous analgesic drug from AFT Pharmaceuticals.
tibet weixinkang pharmaceutical (603676.SH) announced that its wholly-owned subsidiary, tibet Zhongwei Chengkang Pharmaceutical Co., Ltd. (“Zhongwei Cheng...
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary receives drug clinical trial approval notice.
On September 6th, Gelunhui announced that its wholly-owned subsidiary, Beijing Weixinkang Pharmaceutical Research and Development Co., Ltd. (referred to as "Tibet Weixinkang"), has received the approved and issued Drug Clinical Trial Approval Notice for Deoxycholic Acid Injection from the National Medical Products Administration. The deoxycholic acid injection declared by Tibet Weixinkang, a wholly-owned subsidiary of the company, is developed based on Belkyra, a reference preparation marketed by Allergan Pharmaceuticals International/AbbVie S.r.l. Its indication is for improving adults
Express News | Tibet Weixinkang Pharmaceutical: Subsidiary approved for clinical trial of deoxycholic acid injection.
Tibet Weixinkang Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Tibet Weixinkang Pharmaceutical Co., Ltd.
Tibet Weixinkang Pharmaceutical (603676.SH): The net income in the first half of the year was 0.163 billion yuan, an increase of 21.98% year-on-year.
On August 27, Gelonhui reported that Tibet Weixinkang Pharmaceutical (603676.SH) released its 2024 interim report. During the reporting period, the company achieved revenue of 0.633 billion yuan, a decrease of 15.5% year-on-year; net income attributable to the parent company was 0.163 billion yuan, an increase of 21.98% year-on-year; non-GAAP net income was 0.116 billion yuan, a decrease of 11.67% year-on-year; basic earnings per share were 0.38 yuan.
Tibet Weixinkang Pharmaceutical (603676.SH) has released its half-year results, with a net income of 0.163 billion yuan, a year-on-year increase of 21.98%.
Tibet Weixinkang Pharmaceutical (603676.SH) released its semi-annual report for 2024, and during the reporting period, the company achieved a revenue of 0.633 billion...
Express News | Tibet Weixinkang Pharmaceutical: The net income attributable to the parent company in the first half of the year was 0.163 billion yuan, a year-on-year increase of 21.98%.
Tibet Weixinkang Pharmaceutical (603676.SH): "Mannitol Fructose Injection" approved for clinical trials.
Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. has acquired...
Analysis
Price Target
No Data
No Data